Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BTX-A and Mirror Therapy in Chronic Stroke Spasticity
NCT07331844Completed
- Sponsor
- Fatih Sultan Mehmet Training and Research Hospital
- Start
- May 2024
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, double-blind trial of botulinum toxin type A in spastic hemiplegia and stroke (2 arms), sponsored by Fatih Sultan Mehmet Training and Research Hospital. Primary endpoint: Fugl-Meyer Assessment at 6 months. Started May 2024; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
spastic hemiplegiastroke
Beyond the preview
Go deeper on NCT07331844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07331844.